Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
Traverse Biosciences receives $205,709 Phase I STTR Award
January 28, 2015
Traverse Biosciences, founded by the Center’s first appointed BioEntrepreneur-in-Residence Joseph Scaduto, was just awarded a $205,709, Phase I Small Business Technology Transfer (STTR) Award in Partnership with the School of Dental Medicine at Stony Brook University, to evaluate the effectiveness of the company’s lead drug candidate for the treatment of periodontal disease. This is the second Phase I STTR award for Traverse Biosciences this year. The research will be led by Lorne Golub, DMD, MD (Honorary) in the Department of Oral Biology and Pathology, and Ying Gu, PhD, DDS, in the Department of General Dentistry, who will serve as co-principle investigators on the award, in close collaboration with Traverse Biosciences.
“I congratulate Traverse Biosciences on securing a second STTR award to advance their product development and commercialization efforts,” stated Dr. Clinton Rubin, Director of the New York State Center for Biotechnology at Stony Brook University. He added, “STTR funding represents a significant milestone for graduates of our burgeoning BioEntrepreneur-in-Residence program, which is meant to impact the innovation economy and entrepreneurial ecosystem in the region.”
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4373
[post_author] => 4
[post_date] => 2024-02-08 15:17:50
[post_date_gmt] => 2024-02-08 20:17:50
[post_content] =>
Save the date to join us in New York City for the expanded, two-day Life Sciences Summit™ 2024! Visit lifesciencessummit.org for program & registration updates.
[post_title] => Save the Date! LSS 2024: October 8-9th!
[post_excerpt] => Save the date to join us in New York City for the expanded, two-day Life Sciences Summit™ 2024!
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => save-the-date-lss-2024-october-9th
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:48:53
[post_modified_gmt] => 2024-11-19 15:48:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4373
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 2997
[post_author] => 4
[post_date] => 2018-07-02 19:00:11
[post_date_gmt] => 2018-07-02 19:00:11
[post_content] => Former Pfizer Senior Scientist and Scout Anton Xavier has joined the Center for Biotechnology in the role of Assistant Director of Technology and Business Development. Within this role at the Center, Anton will focus on the development and implementation of technology and business development strategies that will increase sponsored research, company formation, strategic alliances, and investment with external partners. Anton will also provide oversight to the Center’s Commercialization Associates offering technology / business development services and education to entrepreneurial faculty and emerging companies.
During his tenure at Pfizer, Anton had duties within the External Science and Innovation group (ES&I) focusing on sourcing, screening, and evaluating early through to late stage (inter)national biopharma ventures, entrepreneurial academic PI technology, private/public/local government funded life science initiatives, and funding vehicles which aligned with Pfizer’s R&D interest for investment and strategic partnerships. Additionally, Anton led efforts within Pfizer R&D from discovery through to late stage development of targeted therapeutics for oncology indications.
Prior to Pfizer, Anton’s experience was within a wider field of bioscience, including regenerative medicine, infectious disease, and cardiovascular biology where he developed multiple therapeutic, platform, and diagnostic innovations for military and industrial needs.
Anton is currently a mentor and adjunct faculty member for early stage life science ventures with E-Lab NYC, ABCT (Accelerator for Biosciences in Connecticut), NSF’s I-Corps program, the British Consulate NYC, Business France, and Cornell / Columbia University, where he provides critical industry based science, strategy, and business development input for bio-venture development.
Anton earned a Master’s degree in Business Administration (MBA) from Cornell University’s Johnson Graduate School of Management, a Master of Science (MSc) in Toxicology from Imperial College London and a Bachelor of Science in Biochemistry with Microbiology from Queen Mary University of London.
Anton can be reached at the Center for Biotechnology by emailing anton.xavier@stonybrook.edu
[post_title] => Anton Xavier Joins CFB in Technology and Business Development Role
[post_excerpt] => Former Pfizer Senior Scientist and Scout will focus on the development and implementation of technology and business development strategies.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => anton-xavier-joins-cfb-in-technology-and-business-development-role
[to_ping] =>
[pinged] =>
[post_modified] => 2018-07-02 19:00:40
[post_modified_gmt] => 2018-07-02 19:00:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2997
[menu_order] => 120
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 3422
[post_author] => 3
[post_date] => 2020-01-15 14:35:02
[post_date_gmt] => 2020-01-15 14:35:02
[post_content] => The IndieBio life sciences accelerator has officially launched in New York and is now accepting applications until March 1st. Each team accepted into the program will receive $250K, lab and co-working space and mentorship during the four-month program that kicks off in April 2020. IndieBio is looking for early-stage companies where biology is the underlying technology, which includes therapeutics, devices, diagnostics, computational biology as well as consumer and industrial applications, such as plant-based foods, cellular agriculture. Therapeutics companies accepted into IndieBio New York are eligible to receive up to $2 million.
IndieBio, the world’s first life sciences accelerator, was created by venture fund SOSV in 2014. In the past five years, SOSV/IndieBio has backed nearly 200 life science startups with a combined valuation of over $3 billion, raising more than $700 million and employing over 2,000 people.
[post_title] => Life Science Accelerator IndieBio Launches in NYC
[post_excerpt] => New life science accelerator has launched in New York City, offering space, financing and more. Applications open and accepted until March 1, 2020.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => life-science-accelerator-indiebio-launches-in-nyc
[to_ping] =>
[pinged] =>
[post_modified] => 2020-01-15 14:35:02
[post_modified_gmt] => 2020-01-15 14:35:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3422
[menu_order] => 78
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
